May 12, 2017 / 12:52 PM / 6 months ago

BRIEF-Steadymed reports Q1 loss per share $0.92

May 12 (Reuters) - Steadymed Ltd

* Steadymed reports first quarter 2017 financial results and provides corporate update

* Q1 loss per share $0.92

* On track to file a new drug application (NDA) for trevyent for treatment of pulmonary arterial hypertension (PAH) in Q2 2017

* Recorded licensing revenues of $315,000 in Q1 of 2017, compared to $375,000 revenues in Q1 of 2016. Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below